4 stories mentioning SHA:603392Updated 16d ago
Every FINWIRES story that references SHA:603392, newest first.
Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) subsidiary Wantai Canghai has submitted a prequalification application with the World Health Organization for its nine-valent human papillomavirus (HPV) vaccine, according to a Tuesday filing with the Shanghai bourse.Shares of the drugmaker declined 2% in recent trade.
Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) announced that its nine-valent human papillomavirus (HPV) vaccine, Cecolin 9, has completed market access across the 31 provinces, autonomous regions and municipalities in China, excluding Hong Kong, Macao and Taiwan.The vaccine has entered about 2,300 CDC centers and covers about 13,000 vaccination points nationwide, according to a Sunday filing with the Shanghai bourse.Shares of the drugmaker rose nearly 5% in recent trade.
Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) posted first-quarter attributable net loss of 43 million yuan, compared with 53 million yuan the previous year.Loss per share narrowed to 0.03 yuan from 0.04 yuan, according to a Tuesday filing with the Shanghai bourse.Revenue rose 31% year over year to 523 million yuan from 401 million yuan.Shares of the drug manufacturer were down 3% in recent trade.
Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) swung to an attributable loss of 398.3 million yuan in 2025 from an attributable profit of 106.2 million yuan in 2024, according to a Tuesday filing with the Shanghai bourse.The drug manufacturer logged a loss per share of 0.31 yuan compared with earnings per share of 0.08 yuan in the previous year.Operating income declined 19% year over year to 1.82 billion yuan from 2.25 billion yuan.Shares decreased 4% during morning trading on Tuesday.
